• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Actinium Pharmaceuticals Inc. (Delaware)

    11/4/24 11:47:21 AM ET
    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email
    SC 13G 1 UnitedStates_13G__ActiniumPh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Actinium Pharmaceuticals Inc (Title of Class of Securities) Common Stock (CUSIP Number) 00507W206 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 00507W206 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 48,600 (7) Sole dispositive power 1,567,507 (8) Shared dispositive power 57,493 (9) Aggregate amount beneficially owned by each reporting person 1,625,000 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.21% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Actinium Pharmaceuticals Inc Item 1(b) Address of issuer's principal executive offices: 100 Park Avenue, 23rd Floor New York, NY 10017 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 00507W206 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 1,625,000 (b) Percent of class: 5.21% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 1,625,000 (b) Percent of class: 5.21% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 48,600 (iii) Sole power to dispose or to direct the disposition of: 1,567,507 (iv) Shared power to dispose or to direct the disposition of: 57,493 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Se
    Get the next $ATNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNM

    DatePrice TargetRatingAnalyst
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    5/14/2024$25.00Overweight
    Stephens
    9/6/2023$11.60Buy
    HSBC Securities
    2/21/2023Outperform → Mkt Perform
    William Blair
    9/8/2022$20.00Overweight
    Cantor Fitzgerald
    8/25/2022$16.00Buy
    B. Riley Securities
    8/3/2021$57.00 → $45.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ATNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

      -       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy -       Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy -       Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK, May 6

      5/6/25 8:45:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

      -  Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working -  ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option -  ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs NEW YORK, Apr

      4/28/25 8:30:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

      Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML modelsActimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignanciesActimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCINEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceutical

      4/28/25 8:00:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Steinhart Richard I

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:33 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chell Jeffrey W.

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:19 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Almenoff June Sherie

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:02 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Financials

    Live finance-specific insights

    See more
    • Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

      -  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed

      11/18/24 8:00:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

      -  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm -  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients -  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 -  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover -  Iomab-B was

      2/18/23 4:30:00 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

      -  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,

      2/14/23 7:30:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

      Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of

      3/27/23 7:00:00 AM ET
      $ATNM
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

      -Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development

      11/2/22 8:17:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

      SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

      11/12/24 1:33:16 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

      SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

      11/8/24 6:51:04 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Actinium Pharmaceuticals Inc. (Delaware)

      SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)

      11/4/24 11:47:21 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Actinum Pharma downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

      8/7/24 12:40:34 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Actinum Pharma with a new price target

      Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:54:25 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HSBC Securities initiated coverage on Actinum Pharma with a new price target

      HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60

      9/6/23 7:41:39 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)

      10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      5/9/25 5:27:35 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      5/9/25 5:00:08 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Actinium Pharmaceuticals Inc. (Delaware)

      10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      3/31/25 5:00:42 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care